Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-02

AUTHORS

Juan Martin-Liberal, Antonio López-Pousa, Javier Martínez-Trufero, Javier Martín-Broto, Ricardo Cubedo, Javier Lavernia, Andrés Redondo, José Antonio López-Martín, Nùria Mulet-Margalef, Xavier Sanjuan, Òscar M. Tirado, Xavier Garcia-del-Muro

ABSTRACT

BACKGROUND: Gemcitabine plus sirolimus enhances apoptosis in vitro and increases anti-tumor efficacy in vivo in soft-tissue sarcoma (STS) models. OBJECTIVE: The objective of this study was to evaluate the activity and toxicity of the combination of gemcitabine plus sirolimus in patients with STS after failure of standard chemotherapy. PATIENTS AND METHODS: Advanced STS patients, previously treated with doxorubicin and/or ifosfamide, were included in this single-arm phase II study. Patients received gemcitabine 800 mg/m2 intravenously (iv) at 10 mg/m2/min on days 1 and 8 every 3 weeks plus sirolimus 5 mg daily orally (po). After enrolment of the first 12 patients, the study protocol was amended due to toxicity and the starting dose of sirolimus was reduced to 3 mg daily po. Archival tumor samples were analyzed for extracellular signal-regulated kinase 1 and 2 (ERK1/2) expression and correlated with outcome. The primary endpoint was progression-free rate (PFR) at 3 months. RESULTS: From May 2012 to May 2013, 28 patients were enrolled at eight centers. PFR at 3 and 6 months was 44% and 20%, respectively, with 12 patients being free of progression at 3 months. Median progression-free survival (PFS) was 1.85 months (95% confidence interval [CI] 0.73-2.97) and median overall survival (OS) was 9.2 months (95% CI 5.8-12.5). No responses were observed. The most common grade 3-4 hematologic toxicities were neutropenia (48%) and leukopenia (41%) and the most frequent grade 3 non-hematologic toxicities were infection (18.5%), transaminitis (15%), fatigue (11%), and pneumonitis (11%). ERK1/2 expression was significantly correlated with PFS (p = 0.026). CONCLUSIONS: The combination of gemcitabine and sirolimus is an active treatment in STS. Further investigation is warranted. ClinicalTrials.gov identifier: NCT01684449. More... »

PAGES

81-87

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-017-0539-9

DOI

http://dx.doi.org/10.1007/s11523-017-0539-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092996951

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29177953


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut Catal\u00e0 d'Oncologia", 
          "id": "https://www.grid.ac/institutes/grid.418701.b", 
          "name": [
            "Medical Oncology Department, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron University Hospital, 08035, Barcelona, Spain", 
            "Sarcoma, Melanoma and Genitourinary Tumors Unit, Institut Catal\u00e0 d\u2019Oncologia L\u2019Hospitalet, Avda Gran Via Km 2.7, 08907 L\u2019Hospitalet, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin-Liberal", 
        "givenName": "Juan", 
        "id": "sg:person.01165767756.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165767756.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital de Sant Pau", 
          "id": "https://www.grid.ac/institutes/grid.413396.a", 
          "name": [
            "Cancer Medicine Department, Hospital de la Santa Creu i Sant Pau, 08026, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00f3pez-Pousa", 
        "givenName": "Antonio", 
        "id": "sg:person.01074340177.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074340177.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario Miguel Servet", 
          "id": "https://www.grid.ac/institutes/grid.411106.3", 
          "name": [
            "Medical Oncology Department, Hospital Universitario Miguel Servet, 50009, Zaragoza, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mart\u00ednez-Trufero", 
        "givenName": "Javier", 
        "id": "sg:person.01156301535.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156301535.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Biomedicine of Seville", 
          "id": "https://www.grid.ac/institutes/grid.414816.e", 
          "name": [
            "Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo/CSIC/Universidad de Sevilla, 41013, Sevilla, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mart\u00edn-Broto", 
        "givenName": "Javier", 
        "id": "sg:person.01244367567.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244367567.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario Puerta de Hierro Majadahonda", 
          "id": "https://www.grid.ac/institutes/grid.73221.35", 
          "name": [
            "Medical Oncology Department, Hospital Puerta de Hierro, 28222, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cubedo", 
        "givenName": "Ricardo", 
        "id": "sg:person.0662375134.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662375134.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda", 
          "id": "https://www.grid.ac/institutes/grid.418082.7", 
          "name": [
            "Medical Oncology Department, Instituto Valenciano de Oncolog\u00eda, 46009, Valencia, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lavernia", 
        "givenName": "Javier", 
        "id": "sg:person.0614751141.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614751141.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario La Paz", 
          "id": "https://www.grid.ac/institutes/grid.81821.32", 
          "name": [
            "Medical Oncology Department, Hospital Universitario La Paz, 28046, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Redondo", 
        "givenName": "Andr\u00e9s", 
        "id": "sg:person.01066140724.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066140724.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario 12 De Octubre", 
          "id": "https://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Medical Oncology Department, Hospital 12 de Octubre, 28041, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00f3pez-Mart\u00edn", 
        "givenName": "Jos\u00e9 Antonio", 
        "id": "sg:person.0664251552.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664251552.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Catal\u00e0 d'Oncologia", 
          "id": "https://www.grid.ac/institutes/grid.418701.b", 
          "name": [
            "Medical Oncology Department, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron University Hospital, 08035, Barcelona, Spain", 
            "Sarcoma, Melanoma and Genitourinary Tumors Unit, Institut Catal\u00e0 d\u2019Oncologia L\u2019Hospitalet, Avda Gran Via Km 2.7, 08907 L\u2019Hospitalet, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mulet-Margalef", 
        "givenName": "N\u00f9ria", 
        "id": "sg:person.01051446743.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051446743.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bellvitge University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411129.e", 
          "name": [
            "Pathology Department, Bellvitge University Hospital, 08907, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sanjuan", 
        "givenName": "Xavier", 
        "id": "sg:person.0671331506.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671331506.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Barcelona", 
          "id": "https://www.grid.ac/institutes/grid.5841.8", 
          "name": [
            "Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), CIBERONC, Universitat de Barcelona, Avda Gran Via Km 2.7, 08907 L\u2019Hospitalet, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tirado", 
        "givenName": "\u00d2scar M.", 
        "id": "sg:person.0631430764.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631430764.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Barcelona", 
          "id": "https://www.grid.ac/institutes/grid.5841.8", 
          "name": [
            "Sarcoma, Melanoma and Genitourinary Tumors Unit, Institut Catal\u00e0 d\u2019Oncologia L\u2019Hospitalet, Avda Gran Via Km 2.7, 08907 L\u2019Hospitalet, Barcelona, Spain", 
            "Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), CIBERONC, Universitat de Barcelona, Avda Gran Via Km 2.7, 08907 L\u2019Hospitalet, Barcelona, Spain", 
            "Universitat de Barcelona, 08036, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garcia-del-Muro", 
        "givenName": "Xavier", 
        "id": "sg:person.01124513223.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124513223.73"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.drup.2007.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006901712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)30587-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009229330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2014.370", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009913903", 
          "https://doi.org/10.1038/bjc.2014.370"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2011-0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013325401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-005-3537-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013812554", 
          "https://doi.org/10.1007/s10637-005-3537-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-005-3537-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013812554", 
          "https://doi.org/10.1007/s10637-005-3537-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014023118", 
          "https://doi.org/10.1038/nrc839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014023118", 
          "https://doi.org/10.1038/nrc839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00491-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015448950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00491-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015448950"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-008-0723-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016045487", 
          "https://doi.org/10.1007/s00280-008-0723-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-008-0723-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016045487", 
          "https://doi.org/10.1007/s00280-008-0723-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.5766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023713538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-200006000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027203531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-200006000-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027203531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04869", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031370745", 
          "https://doi.org/10.1038/nature04869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04869", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031370745", 
          "https://doi.org/10.1038/nature04869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04869", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031370745", 
          "https://doi.org/10.1038/nature04869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04869", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031370745", 
          "https://doi.org/10.1038/nature04869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1368-7646(02)00120-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032887826"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1368-7646(02)00120-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032887826"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds070", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033190781"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2015.10.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034132335"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00408-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034996744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.6107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039075080"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00398-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041730636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.10.4117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044406195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.1.150", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074511220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.15.3483", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074857560"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091964287"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02", 
    "datePublishedReg": "2018-02-01", 
    "description": "BACKGROUND: Gemcitabine plus sirolimus enhances apoptosis in vitro and increases anti-tumor efficacy in vivo in soft-tissue sarcoma (STS) models.\nOBJECTIVE: The objective of this study was to evaluate the activity and toxicity of the combination of gemcitabine plus sirolimus in patients with STS after failure of standard chemotherapy.\nPATIENTS AND METHODS: Advanced STS patients, previously treated with doxorubicin and/or ifosfamide, were included in this single-arm phase II study. Patients received gemcitabine 800\u00a0mg/m2 intravenously (iv) at 10\u00a0mg/m2/min on days 1 and 8 every 3\u00a0weeks plus sirolimus 5\u00a0mg daily orally (po). After enrolment of the first 12 patients, the study protocol was amended due to toxicity and the starting dose of sirolimus was reduced to 3\u00a0mg daily po. Archival tumor samples were analyzed for extracellular signal-regulated kinase 1 and 2 (ERK1/2) expression and correlated with outcome. The primary endpoint was progression-free rate (PFR) at 3\u00a0months.\nRESULTS: From May 2012 to May 2013, 28 patients were enrolled at eight centers. PFR at 3 and 6\u00a0months was 44% and 20%, respectively, with 12 patients being free of progression at 3\u00a0months. Median progression-free survival (PFS) was 1.85\u00a0months (95% confidence interval [CI] 0.73-2.97) and median overall survival (OS) was 9.2\u00a0months (95% CI 5.8-12.5). No responses were observed. The most common grade 3-4 hematologic toxicities were neutropenia (48%) and leukopenia (41%) and the most frequent grade 3 non-hematologic toxicities were infection (18.5%), transaminitis (15%), fatigue (11%), and pneumonitis (11%). ERK1/2 expression was significantly correlated with PFS (p\u00a0=\u00a00.026).\nCONCLUSIONS: The combination of gemcitabine and sirolimus is an active treatment in STS. Further investigation is warranted. ClinicalTrials.gov identifier: NCT01684449.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11523-017-0539-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "name": "Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study", 
    "pagination": "81-87", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fecfc579d88c7111240f74dbcc21576c78be55a3cec7842b97e1bdd08a873fda"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29177953"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101270595"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-017-0539-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092996951"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-017-0539-9", 
      "https://app.dimensions.ai/details/publication/pub.1092996951"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000602.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s11523-017-0539-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0539-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0539-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0539-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0539-9'


 

This table displays all metadata directly associated to this object as RDF triples.

247 TRIPLES      21 PREDICATES      51 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-017-0539-9 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N9a0bf59b0cef4f9ba1010f0c12e8033b
4 schema:citation sg:pub.10.1007/s00280-008-0723-9
5 sg:pub.10.1007/s10637-005-3537-1
6 sg:pub.10.1038/bjc.2014.370
7 sg:pub.10.1038/nature04869
8 sg:pub.10.1038/nrc839
9 https://doi.org/10.1016/j.critrevonc.2015.10.020
10 https://doi.org/10.1016/j.drup.2007.11.003
11 https://doi.org/10.1016/j.ejca.2008.10.026
12 https://doi.org/10.1016/s0140-6736(16)30587-6
13 https://doi.org/10.1016/s0959-8049(01)00398-7
14 https://doi.org/10.1016/s0959-8049(01)00408-7
15 https://doi.org/10.1016/s0959-8049(02)00491-4
16 https://doi.org/10.1016/s1368-7646(02)00120-6
17 https://doi.org/10.1093/annonc/mds070
18 https://doi.org/10.1093/annonc/mdx536
19 https://doi.org/10.1097/00001813-200006000-00002
20 https://doi.org/10.1200/jco.1999.17.1.150
21 https://doi.org/10.1200/jco.2001.19.15.3483
22 https://doi.org/10.1200/jco.2006.10.4117
23 https://doi.org/10.1200/jco.2010.33.6107
24 https://doi.org/10.1200/jco.2012.45.5766
25 https://doi.org/10.1634/theoncologist.2011-0467
26 schema:datePublished 2018-02
27 schema:datePublishedReg 2018-02-01
28 schema:description BACKGROUND: Gemcitabine plus sirolimus enhances apoptosis in vitro and increases anti-tumor efficacy in vivo in soft-tissue sarcoma (STS) models. OBJECTIVE: The objective of this study was to evaluate the activity and toxicity of the combination of gemcitabine plus sirolimus in patients with STS after failure of standard chemotherapy. PATIENTS AND METHODS: Advanced STS patients, previously treated with doxorubicin and/or ifosfamide, were included in this single-arm phase II study. Patients received gemcitabine 800 mg/m2 intravenously (iv) at 10 mg/m2/min on days 1 and 8 every 3 weeks plus sirolimus 5 mg daily orally (po). After enrolment of the first 12 patients, the study protocol was amended due to toxicity and the starting dose of sirolimus was reduced to 3 mg daily po. Archival tumor samples were analyzed for extracellular signal-regulated kinase 1 and 2 (ERK1/2) expression and correlated with outcome. The primary endpoint was progression-free rate (PFR) at 3 months. RESULTS: From May 2012 to May 2013, 28 patients were enrolled at eight centers. PFR at 3 and 6 months was 44% and 20%, respectively, with 12 patients being free of progression at 3 months. Median progression-free survival (PFS) was 1.85 months (95% confidence interval [CI] 0.73-2.97) and median overall survival (OS) was 9.2 months (95% CI 5.8-12.5). No responses were observed. The most common grade 3-4 hematologic toxicities were neutropenia (48%) and leukopenia (41%) and the most frequent grade 3 non-hematologic toxicities were infection (18.5%), transaminitis (15%), fatigue (11%), and pneumonitis (11%). ERK1/2 expression was significantly correlated with PFS (p = 0.026). CONCLUSIONS: The combination of gemcitabine and sirolimus is an active treatment in STS. Further investigation is warranted. ClinicalTrials.gov identifier: NCT01684449.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N75fb627ddf7546cda35f70932b491a75
33 Nd3ee16be48c7446da62ac98f43638f68
34 sg:journal.1036678
35 schema:name Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study
36 schema:pagination 81-87
37 schema:productId N01401b137fcd4308930a1e35e93914bd
38 N3c0a9276b7044d3bb179aa009ef09e0e
39 N638881a15d114b54b3e74da75015cf26
40 Na1903783287f43ecbd0489cb2f8bb328
41 Nc791e7540771478992cda7e6aac5033d
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092996951
43 https://doi.org/10.1007/s11523-017-0539-9
44 schema:sdDatePublished 2019-04-10T13:32
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher N2df5a0e4cfe34407a48da997a54fe4ef
47 schema:url http://link.springer.com/10.1007/s11523-017-0539-9
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N01401b137fcd4308930a1e35e93914bd schema:name doi
52 schema:value 10.1007/s11523-017-0539-9
53 rdf:type schema:PropertyValue
54 N101eed688a054d0f96381d2a4a4e69cb rdf:first sg:person.01066140724.83
55 rdf:rest N4eacaba3601a41228640e98a7ee5689c
56 N1eca078220c741b193b4e714f0135b6b rdf:first sg:person.0631430764.39
57 rdf:rest N58db22f6e424472aaf002d4e808fe711
58 N2df5a0e4cfe34407a48da997a54fe4ef schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 N3c0a9276b7044d3bb179aa009ef09e0e schema:name pubmed_id
61 schema:value 29177953
62 rdf:type schema:PropertyValue
63 N47b99991d62746aea69edad362fa45f7 rdf:first sg:person.01156301535.52
64 rdf:rest N929e12bbc95c445d8622609f472f5990
65 N4eacaba3601a41228640e98a7ee5689c rdf:first sg:person.0664251552.02
66 rdf:rest Nfc1cc04ad9a743178ac45bf2ce8590d4
67 N4fcb8e0f10fc461eb86cf162aaf1531b rdf:first sg:person.0614751141.45
68 rdf:rest N101eed688a054d0f96381d2a4a4e69cb
69 N56c728ecb8554eae826991cdd7ec1dfb rdf:first sg:person.01074340177.09
70 rdf:rest N47b99991d62746aea69edad362fa45f7
71 N58db22f6e424472aaf002d4e808fe711 rdf:first sg:person.01124513223.73
72 rdf:rest rdf:nil
73 N638881a15d114b54b3e74da75015cf26 schema:name readcube_id
74 schema:value fecfc579d88c7111240f74dbcc21576c78be55a3cec7842b97e1bdd08a873fda
75 rdf:type schema:PropertyValue
76 N75fb627ddf7546cda35f70932b491a75 schema:issueNumber 1
77 rdf:type schema:PublicationIssue
78 N886a0f7e1919467487bed3160389886e rdf:first sg:person.0671331506.49
79 rdf:rest N1eca078220c741b193b4e714f0135b6b
80 N929e12bbc95c445d8622609f472f5990 rdf:first sg:person.01244367567.45
81 rdf:rest Nf91e3d3b1a2f457ca434b149233a1faf
82 N9a0bf59b0cef4f9ba1010f0c12e8033b rdf:first sg:person.01165767756.07
83 rdf:rest N56c728ecb8554eae826991cdd7ec1dfb
84 Na1903783287f43ecbd0489cb2f8bb328 schema:name dimensions_id
85 schema:value pub.1092996951
86 rdf:type schema:PropertyValue
87 Nc791e7540771478992cda7e6aac5033d schema:name nlm_unique_id
88 schema:value 101270595
89 rdf:type schema:PropertyValue
90 Nd3ee16be48c7446da62ac98f43638f68 schema:volumeNumber 13
91 rdf:type schema:PublicationVolume
92 Nf91e3d3b1a2f457ca434b149233a1faf rdf:first sg:person.0662375134.32
93 rdf:rest N4fcb8e0f10fc461eb86cf162aaf1531b
94 Nfc1cc04ad9a743178ac45bf2ce8590d4 rdf:first sg:person.01051446743.50
95 rdf:rest N886a0f7e1919467487bed3160389886e
96 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
97 schema:name Medical and Health Sciences
98 rdf:type schema:DefinedTerm
99 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
100 schema:name Oncology and Carcinogenesis
101 rdf:type schema:DefinedTerm
102 sg:journal.1036678 schema:issn 1776-2596
103 1776-260X
104 schema:name Targeted Oncology
105 rdf:type schema:Periodical
106 sg:person.01051446743.50 schema:affiliation https://www.grid.ac/institutes/grid.418701.b
107 schema:familyName Mulet-Margalef
108 schema:givenName Nùria
109 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051446743.50
110 rdf:type schema:Person
111 sg:person.01066140724.83 schema:affiliation https://www.grid.ac/institutes/grid.81821.32
112 schema:familyName Redondo
113 schema:givenName Andrés
114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066140724.83
115 rdf:type schema:Person
116 sg:person.01074340177.09 schema:affiliation https://www.grid.ac/institutes/grid.413396.a
117 schema:familyName López-Pousa
118 schema:givenName Antonio
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074340177.09
120 rdf:type schema:Person
121 sg:person.01124513223.73 schema:affiliation https://www.grid.ac/institutes/grid.5841.8
122 schema:familyName Garcia-del-Muro
123 schema:givenName Xavier
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124513223.73
125 rdf:type schema:Person
126 sg:person.01156301535.52 schema:affiliation https://www.grid.ac/institutes/grid.411106.3
127 schema:familyName Martínez-Trufero
128 schema:givenName Javier
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156301535.52
130 rdf:type schema:Person
131 sg:person.01165767756.07 schema:affiliation https://www.grid.ac/institutes/grid.418701.b
132 schema:familyName Martin-Liberal
133 schema:givenName Juan
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165767756.07
135 rdf:type schema:Person
136 sg:person.01244367567.45 schema:affiliation https://www.grid.ac/institutes/grid.414816.e
137 schema:familyName Martín-Broto
138 schema:givenName Javier
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244367567.45
140 rdf:type schema:Person
141 sg:person.0614751141.45 schema:affiliation https://www.grid.ac/institutes/grid.418082.7
142 schema:familyName Lavernia
143 schema:givenName Javier
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614751141.45
145 rdf:type schema:Person
146 sg:person.0631430764.39 schema:affiliation https://www.grid.ac/institutes/grid.5841.8
147 schema:familyName Tirado
148 schema:givenName Òscar M.
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631430764.39
150 rdf:type schema:Person
151 sg:person.0662375134.32 schema:affiliation https://www.grid.ac/institutes/grid.73221.35
152 schema:familyName Cubedo
153 schema:givenName Ricardo
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662375134.32
155 rdf:type schema:Person
156 sg:person.0664251552.02 schema:affiliation https://www.grid.ac/institutes/grid.144756.5
157 schema:familyName López-Martín
158 schema:givenName José Antonio
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664251552.02
160 rdf:type schema:Person
161 sg:person.0671331506.49 schema:affiliation https://www.grid.ac/institutes/grid.411129.e
162 schema:familyName Sanjuan
163 schema:givenName Xavier
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671331506.49
165 rdf:type schema:Person
166 sg:pub.10.1007/s00280-008-0723-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016045487
167 https://doi.org/10.1007/s00280-008-0723-9
168 rdf:type schema:CreativeWork
169 sg:pub.10.1007/s10637-005-3537-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013812554
170 https://doi.org/10.1007/s10637-005-3537-1
171 rdf:type schema:CreativeWork
172 sg:pub.10.1038/bjc.2014.370 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009913903
173 https://doi.org/10.1038/bjc.2014.370
174 rdf:type schema:CreativeWork
175 sg:pub.10.1038/nature04869 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031370745
176 https://doi.org/10.1038/nature04869
177 rdf:type schema:CreativeWork
178 sg:pub.10.1038/nrc839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014023118
179 https://doi.org/10.1038/nrc839
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.critrevonc.2015.10.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034132335
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.drup.2007.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006901712
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/s0140-6736(16)30587-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009229330
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/s0959-8049(01)00398-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041730636
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/s0959-8049(01)00408-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034996744
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/s0959-8049(02)00491-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015448950
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/s1368-7646(02)00120-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032887826
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1093/annonc/mds070 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033190781
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1093/annonc/mdx536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091964287
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1097/00001813-200006000-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027203531
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1200/jco.1999.17.1.150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074511220
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1200/jco.2001.19.15.3483 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074857560
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1200/jco.2006.10.4117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044406195
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1200/jco.2010.33.6107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039075080
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1200/jco.2012.45.5766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023713538
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1634/theoncologist.2011-0467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013325401
214 rdf:type schema:CreativeWork
215 https://www.grid.ac/institutes/grid.144756.5 schema:alternateName Hospital Universitario 12 De Octubre
216 schema:name Medical Oncology Department, Hospital 12 de Octubre, 28041, Madrid, Spain
217 rdf:type schema:Organization
218 https://www.grid.ac/institutes/grid.411106.3 schema:alternateName Hospital Universitario Miguel Servet
219 schema:name Medical Oncology Department, Hospital Universitario Miguel Servet, 50009, Zaragoza, Spain
220 rdf:type schema:Organization
221 https://www.grid.ac/institutes/grid.411129.e schema:alternateName Bellvitge University Hospital
222 schema:name Pathology Department, Bellvitge University Hospital, 08907, Barcelona, Spain
223 rdf:type schema:Organization
224 https://www.grid.ac/institutes/grid.413396.a schema:alternateName Hospital de Sant Pau
225 schema:name Cancer Medicine Department, Hospital de la Santa Creu i Sant Pau, 08026, Barcelona, Spain
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.414816.e schema:alternateName Institute of Biomedicine of Seville
228 schema:name Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013, Sevilla, Spain
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.418082.7 schema:alternateName Fundación Instituto Valenciano de Oncología
231 schema:name Medical Oncology Department, Instituto Valenciano de Oncología, 46009, Valencia, Spain
232 rdf:type schema:Organization
233 https://www.grid.ac/institutes/grid.418701.b schema:alternateName Institut Català d'Oncologia
234 schema:name Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, 08035, Barcelona, Spain
235 Sarcoma, Melanoma and Genitourinary Tumors Unit, Institut Català d’Oncologia L’Hospitalet, Avda Gran Via Km 2.7, 08907 L’Hospitalet, Barcelona, Spain
236 rdf:type schema:Organization
237 https://www.grid.ac/institutes/grid.5841.8 schema:alternateName University of Barcelona
238 schema:name Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), CIBERONC, Universitat de Barcelona, Avda Gran Via Km 2.7, 08907 L’Hospitalet, Barcelona, Spain
239 Sarcoma, Melanoma and Genitourinary Tumors Unit, Institut Català d’Oncologia L’Hospitalet, Avda Gran Via Km 2.7, 08907 L’Hospitalet, Barcelona, Spain
240 Universitat de Barcelona, 08036, Barcelona, Spain
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.73221.35 schema:alternateName Hospital Universitario Puerta de Hierro Majadahonda
243 schema:name Medical Oncology Department, Hospital Puerta de Hierro, 28222, Madrid, Spain
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.81821.32 schema:alternateName Hospital Universitario La Paz
246 schema:name Medical Oncology Department, Hospital Universitario La Paz, 28046, Madrid, Spain
247 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...